Nivolumab — Drug Intelligence | 205 EU Trials

Filter these 205 trials by condition, phase, country and more.

Open in Search →

205 Registered trials

76 Recruiting

109 Completed trials

107 Sponsors

23 Countries

Phase III

Phase II

Phase I/II

Phase III: 57 Phase II/III: 10 Phase II: 80 Phase I/II: 26 Phase IV: 11 Phase I (Other): 3 Phase I (FiH): 18

Oversight events:

5 serious breaches 12 temporary halts 3 urgent safety measures 1 unexpected event across 10 trials

View oversight register →

Indications tested

Non-small cell lung cancer 11 Hepatocellular carcinoma 7 Gastric cancer 5 Bladder cancer 5 Renal cell carcinoma 5 Colorectal cancer 4 Uveal melanoma 4 Malignant melanoma stage III 4 Gastrooesophageal cancer 3 Head and neck cancer 3 Metastatic renal cell carcinoma 3 Malignant melanoma stage IV 3

Sponsors using this IMP

Bristol-Myers Squibb Services Unlimited Company 23 Bristol Myers Squibb International Corporation 19 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 11 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 5 Institut Gustave Roussy 5 CatalYm GmbH 4 Fundacion GECP 4 Intergroupe Francophone De Cancerologie Thoracique 4 Unicancer 4 Centre Leon Berard 3 Exelixis Inc. 3 Karolinska University Hospital 3

All trials — page 9

205 total

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended

2023-509711-83-00 Phase III 7 countries Bristol-Myers Squibb Services Unlimited Company
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended

2023-508757-75-00 Phase III 7 countries Bristol Myers Squibb International Corporation
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer Ended

2022-502909-15-00 Phase II 1 country Bristol Myers Squibb International Corporation
CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended

2022-501784-40-00 Phase III 11 countries Bristol-Myers Squibb Services Unlimited Company
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung… Ended

2022-501360-18-00 Phase III 4 countries Bristol-Myers Squibb International Corporation
A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended

2023-509360-24-00 Phase III 10 countries Bristol Myers Squibb International Corporation
CheckMate 274 Ended

2022-500630-29-00 Phase III 13 countries Bristol-Myers Squibb Services Unlimited Company
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended

2023-508067-70-00 Phase I/II 9 countries Bristol Myers Squibb International Corporation
A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended

2023-504761-23-00 Phase III 13 countries Bristol Myers Squibb International Corporation
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer Ended

2024-516004-42-01 Phase II 2 countries Bristol Myers Squibb International Corporation
CheckMate 032:CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 032 Ended

2024-516540-25-00 Phase I/II 1 country Bristol Myers Squibb International Corporation
A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended

2022-503007-22-00 Phase II 5 countries Bristol-Myers Squibb Services Unlimited Company
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA) Ended

2023-503525-19-00 Phase I (Other) 2 countries Akamis Bio Limited

Showing 193–205 of 205 trials

← All drugs A–Z